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IntroductionAU : Pleaseconfirmthatallheadinglevelsarerepresentedcorrectly:
Rabies remains a global public health concern that is responsible for more than 59,000 human
deaths per year [1]. Postexposure prophylaxis (PEP) for humans exposed to rabies virus should
include wound cleansing followed by 1 dose of human rabies immunoglobulin (HRIG) and a
series of cell culture rabies vaccine doses [2]. Symptomatic rabies is nearly always fatal but uni-
versally preventable with appropriate PEP. An estimated 30,000 to 60,000 Americans receive
rabies PEP each year [3]. The stakeholders involved in PEP implementation in the United
States are diverse, creating systematic complexity that creates barriers to accessing care, lacks
coordination, and delivers suboptimal care. Here, we elaborate on 3 issues of (i) access to, (ii)
coordination of, and (iii) delivery of care for suspected rabies exposures; share examples of
contemporary quality initiatives from large health systems; and propose novel solutions.
Access to rabies PEP is limited and variable
Suspected rabies exposures are medical urgencies, which are serious but require relatively few
interventions—thus, most patients presenting to the emergency department (ED) for rabies
PEP are triaged to Emergency Severity Index level 4 (less urgent) or level 5 (nonurgent) [4].
Nevertheless, adequate and timely PEP is mandatory to prevent progression to fatal disease.
Commonly, patients with wounds from an animal encounter will seek initial wound care in
the ED and may be reasonably initiated on rabies PEP during the same ED encounter. There-
fore, many EDs maintain inventory of rabies vaccine and HRIG. However, access to rabies
PEP outside of the ED for less severe cases is limited. Sites that rarely care for patients requir-
ing rabies PEP are not incentivized to maintain inventory of expensive rabies vaccine and
HRIG. Payer reimbursement for clinic visits where rabies vaccine is administered have thin
revenue margins and may lose revenue in some cases, which does not incentivize provider
clinics to stock or administer rabies vaccine. Vaccine is infrequently covered by Medicare Part







Citation: Howington GT, Nguyen H-B, Bookstaver
PB, Akpunonu P, Swan JT (2021) Rabies
postexposure prophylaxis in the United States:
Opportunities to improve access, coordination, and
delivery. PLoS Negl Trop Dis 15(7): e0009461.
https://doi.org/10.1371/journal.pntd.0009461
Editor: Ran Wang, Beijing Children’s Hospital,
Capital Medical University, CHINA
Published: July 15, 2021
Copyright: © 2021 Howington et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Funding: GTH, BB, and PA received stipends and
JTS’s employer received a stipend from Kedrion
Biopharma, Inc. for participation in a human rabies
immune globulin advisory board that directly
supported this manuscript. HBN was an employee
of the funder (Kedrion Biopharma Inc) is now an
employee of AbbVie, and is a co-author who
assisted with preparation of the manuscript. The
funder hired an independent graphic designer to
prepare study figures using source material that
was drafted by the co-authors. The funder had no
other involvement in publication decisions or
manuscript preparation.
B or D plans and often results in high copays for patients. This limits patients’ ability to access
follow-up vaccine doses, obligating them to seek follow-up vaccine doses in medical settings
such as EDs. Typically, only pharmacies associated with travel clinics and EDs stock rabies vac-
cine, and retail pharmacies do not routinely stock HRIG. Due to these challenges in the US’
payer model, patients who seek rabies PEP outside of the ED setting may experience large out-
of-pocket costs or have difficulty finding a care setting with available inventory in rural, subur-
ban, and urban areas.
Coordination of rabies PEP between care settings is lacking
The US’ healthcare system lacks coordination in the chain of care for rabies PEP delivery that
results in unnecessary ED visits, placing an undue burden on patients and payers. Since care
settings outside of the ED provide limited access to HRIG, patients with minor wounds (or no
wounds at all) are often referred to the ED to initiate rabies PEP (Fig 1A). In these cases,
Fig 1. (a) Currently, patients with suspected rabies exposures routinely present or are referred to EDs regardless of
whether they have extensive or minor/no wounds. Ambulatory patients may be referred by less acute healthcare
settings and other stakeholders such as veterinarians, poison control and public health authorities, etc. Patients may be
subsequently referred to community settings to complete PEP regimen of follow-up vaccine doses, but if community
barriers to accessing care exist, patients will be referred back to the initiating ED. (b) Increasing access to PEP
initiation in settings such as urgent, primary, and specialty care could be made possible by local availability or on-
demand provision of HRIG. Patients with minor or no wounds could be adequately initiated on PEP at less acute
settings, reducing burden on EDs. Availability of follow-up vaccination in community settings could further optimize
the care chain and reduce burden on EDs. Boxes with a bold outline indicate a facility that can provide rabies PEP as a
clinical service. ED, emergency department; HRIG, human rabies immunoglobulin; PEP, postexposure prophylaxis.
https://doi.org/10.1371/journal.pntd.0009461.g001
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patients may endure a poor experience including long travel times and ED wait times, and ED
resources are diverted from patients with more urgent complaints. When rabies PEP is initi-
ated in the ED, staff are burdened with developing appropriate referral plans for subsequent
rabies vaccine doses for patients with a variety of geographical and socioeconomic consider-
ations. Unfortunately, due to patients’ inability to obtain rabies vaccine in the community,
many unnecessarily return to the ED for subsequent rabies vaccine doses [5]. Wound manage-
ment is the only aspect of rabies PEP that may require emergency care services. All other
aspects of rabies PEP, including management of minor wounds, can be effectively provided
outside of the ED.
When given, delivery of rabies PEP is not optimal
As a result of access and coordination challenges in the US, EDs have become the de facto
healthcare setting responsible for rabies PEP initiation. However, ED providers see propor-
tionally fewer cases of rabies PEP per year compared to many other conditions. Additionally,
the ED quality infrastructure has not developed extensive clinical decision support and referral
systems for rabies PEP like they have for other diseases (stroke, acute coronary syndrome,
trauma, etc.). Rates of correct and appropriate delivery of PEP (particularly HRIG) remain
low, and many patients with anatomically feasible wounds may not receive HRIG wound infil-
tration in the ED [6,7]. Thus, an opportunity may exist to optimize implementation of care
delivery and coordination.
Wound infiltration with as much HRIG as anatomically feasible to passively neutralize
virus is crucial to bridge the protection gap between exposure and the active immune response to
vaccination. Suboptimal delivery of rabies immunoglobulin, such as incomplete infiltration into
wounds or intramuscular-only administration when a wound exists, may lead to rabies PEP treat-
ment failure [8]. While guidelines agree on the importance of wound infiltration, neither the Cen-
ters for Disease Control and Prevention (CDC) nor the World Health Organization (WHO)
define “anatomically feasible” volumes for infiltration by anatomical site. Similarly, HRIG uses
weight-based dosing, which results in challenges for extremely small or large weights. Small body-
weight (i.e., children) may result in insufficient HRIG volume to optimally infiltrate large wounds.
Large body weight (i.e., obese adults) may result in large volumes of HRIG that need to be deliv-
ered through many intramuscular injection sites. This lack of clarity may drive poor adherence
and treatment gaps, including failure to infiltrate wound sites with HRIG.
Examples of contemporary success from large health system
perspectives
Although not comprehensive, several contemporary successes at large health systems aim to
address some of these issues (Table 1). Several large institutions have implemented clinical
decision support in their electronic medical records to optimize HRIG wound infiltration. The
University of Kentucky HealthCare created a partnership with an affiliated urgent care to refer
patients for subsequent doses of rabies vaccine and reduce unnecessary ED visits. The Houston
Methodist health system utilized clinical decision support within their electronic health medi-
cal record to assist with rabies PEP medication selection and provide standardized administra-
tion instructions for HRIG. Additionally, Prisma Health Midlands created an outpatient
pharmacy referral site within the health system for subsequent doses of rabies vaccine.
Future directions
Flawed chain-of-care coordination leads to unnecessary treatment omission and financial bur-
den on the healthcare system. Across the US, overabundant utilization of EDs for delivery of
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rabies PEP increases overall healthcare expenditure and significantly wastes ED resources. We
identified barriers to implementing optimized referral systems based on acquisition costs of
rabies vaccine and HRIG and lack of prescription insurance coverage of rabies vaccine by
many payers. We also identified the need for guidance to clarify optimal HRIG administration
in heterogeneous populations. We propose several imperatives to optimize patient care.
First, remove clinical and economic barriers to PEP access. As health systems validate effec-
tiveness of clinical decision support built for ED providers, these tools should be broadly dis-
tributed to other EDs and adapted to provide clinical decision support in non-ED care
settings, such as urgent care and primary care. Economic barriers can be mitigated either
through reducing overhead and financial exposure associated with maintaining an inventory
of rabies PEP or through enhanced reimbursement from payers for HRIG and vaccine. Strate-
gies that reduce financial overhead from inventory include distributor consignment programs,
product replacement programs, and “on-demand” delivery.
Second, create a healthcare coordination system for rabies PEP chain of care to reduce
unnecessary ED visits for (1) initiation of rabies PEP when severe wounds or other urgent con-
ditions are not present and (2) subsequent rabies vaccine doses. This could be accomplished
through a publicly accessible registry of healthcare facilities (EDs, urgent care clinics, outpa-
tient clinics, and pharmacies) that commit to providing either rabies vaccine or HRIG. Sites
that provide both rabies vaccine and HRIG would be designated as “rabies PEP initiation
sites,” and sites that provide only rabies vaccine would be designated as “rabies PEP continua-
tion sites.” Rabies PEP initiation sites would need to ensure adequate staff training to deter-
mine which animal exposures require rabies PEP and to provide basic wound care, such as
Table 1. Examples of rabies PEP quality programs in the US.
Health System
(City, State)





1 academic medical center, 6




All EDs within health
system provide HRIG and
rabies vaccine
Patients are provided a flyer that lists
pharmacies and clinics in metro area
that can provide rabies vaccination
Developed an ED order set to assist
with medication selection, dosing, and
administration that emphasizes
infiltrating eligible wounds with HRIG
and avoiding administration of HRIG










All EDs provide HRIG and
rabies vaccine
All rabies PEP patients receive a
patient-specific flyer at ED discharge
that details when to obtain days 3, 7,
and 14 rabies vaccine doses and
specifically instructs patients to
schedule an appointment with the
Urgent Care for subsequent rabies
vaccine doses.
Developed an HRIG order with specific
instructions describing wound
infiltration, importance of avoiding
administration of HRIG and rabies
vaccine at same site, and
recommending against mixing rabies








140,000 visits per year.
Majority of cases are
handled in 1 ED within
system, but urgent supply
dose of HRIG is maintained
at all locations
Patients are provided a hard copy of
the vaccine series prescription in
addition to the faxed or electronic
copy to the outpatient pharmacy
affiliated with the health system. The
vaccine series prescription prompts
the outpatient pharmacy to contact
the patient if doses are not obtained
on the appropriately scheduled
timeline.
Developed an ED order set for both
HRIG and rabies vaccine to facilitate
continuity of the vaccine series at the
affiliated outpatient pharmacy. This
order prompts a faxed prescription to
the outpatient pharmacy for adults or
the Children’s Day Hospital for
pediatrics.
All EDs provide rabies
vaccine
Local zoo staff and veterinarians direct
patients to referral hospital in
healthcare system
ED, emergency department; HRIG, human rabies immunoglobulin; PEP, postexposure prophylaxis.
https://doi.org/10.1371/journal.pntd.0009461.t001
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cleansing and bandages (Fig 1B). Patients could access this website to identify a site that pro-
vides initial healthcare and assessment following an animal exposure. This centralized resource
could be leveraged by healthcare workers to design appropriate referral plans. Registries could
be maintained and validated by agencies at the appropriate health department level.
Third, develop additional volume- and wound-based guidance for HRIG administration to
enable appropriate assessment, triage, and closer adherence to authoritative guidelines. Guid-
ance that describes optimal volumes based on locality and morphology of wounds could sup-
port practical implementation of CDC and WHO recommendations, particularly as guidelines
move away from weight-based dosing [2,9,10]. For example, implementation of revised WHO
guidelines in some European countries (e.g. in the Netherlands) have catalyzed a need for
more granular guidance that describe minimum and maximum volumes of HRIG infiltration
for each wound based on anatomical region [9,11].
Death from rabies is entirely preventable with appropriate care, which should be widely
available. In the US, only 1 to 3 human rabies cases are reported annually, and death from
rabies infection is rare [3]. However, systematic inefficiencies and barriers prevent patients
from accessing appropriate and complete PEP, create unnecessary patient risk, and increase
societal costs. Given the severe consequences from treatment failure and cost of therapy, rabies
PEP should not be neglected by healthcare payers and referral systems in a developed country
such as the US.
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